Optimi
Investors →
01CompanyIncorporated 2020 — British Columbia, Canada

A commercial-stage psychedelic drug manufacturer.

Optimi Health Corp. (CSE: OPTI · OTCQX: OPTHF) produces finished-dose psilocybin and MDMA capsules for regulated therapeutic use. The Company operates a Health Canada GMP-compliant facility in Princeton, British Columbia, and holds a Drug Establishment Licence authorizing commercial manufacture, packaging, testing, and international export of controlled drug products.

Active supply operations began under the Australian Authorized Prescriber Scheme in 2024. Product is dispensed to patients through authorized clinics for post-traumatic stress disorder and treatment-resistant depression.

The Company is structured to scale into additional jurisdictions as regulatory access develops, including the United States upon federal rescheduling.

02What makes us differentFour pillars
01

Commercial today

MDMA and psilocybin capsules in the hands of authorized prescribers in Australia. Revenue recognized since Q2 2024.

02

GMP at the core

Health Canada Drug Establishment Licence. International export authorization. Built to pharmaceutical standards.

03

Direct to clinic

No middlemen. We supply authorized clinics, pharmacies, and clinical trial sponsors directly.

04

Rescheduling-ready

Infrastructure, quality systems, and regulatory posture in place to scale into U.S. therapeutic access as it opens.

03PositioningCommercial-stage, not clinical

Most public psychedelic comparables are drug developers — they burn capital through clinical trials and have not yet crossed into revenue-generating supply. Optimi is already a manufacturer and supplier to regulated access programs, with revenue recognized since Q2 2024.

The question shifts from "will the asset read out?" to "how fast does regulated access expand, and how defensible is the manufacturing position when it does?"

Read the full market primer →

04Leadership & governanceExecutives and board

Dane Stevens

Chief Executive Officer & Co-Founder

CEO since October 2024; co-founder since 2020. Nearly two decades in sourcing, manufacturing, and global distribution. Focused on producing GMP-certified MDMA and natural psilocybin for regulated treatment programs.

Jacob Safarik

Chief Financial Officer

Chartered Professional Accountant (CPA). 16+ years in accounting, project finance, business development, and quality assurance. Responsible for financial strategy, capital allocation, and cost management.

Bryan Safarik

Chief Operating Officer

Nearly two decades of senior management across regulated industries. Former Director of Marine Operations at Ocean Fisheries Ltd. Co-founded a federally licensed cannabis production company. Oversees production and GMP-certified manufacturing.

Dr. Preston Chase

Chief Science Officer

R&D chemist with 25+ years of experience. BSc from University of Victoria; PhD from University of Calgary. 30+ peer-reviewed publications; multiple awarded and pending patents across catalysis, synthesis, and analytical chemistry.

JJ Wilson

Chairman of the Board

Co-founder of Amer Sports. Capital-markets and brand-building track record spanning two decades.

Licence
GMPHealth Canada DEL
Active market
AustraliaTGA APS
Product lines
3capsules
Listings
CSE · OTCQX · FSENasdaq TBD